Preface – ESMO 2016

Silvia Novello, MD, PhD, University of Turin, Italy

Silvia Novello, MD, PhD, University of Turin, Italy

Dear Colleagues,

According to an estimate by the World Health Organization, 1.37 million people worldwide die of lung cancer every year. Both incidence and lung-cancer–related mortality are substantial: to date, primary lung cancer remains the most common malignancy after nonmelanocytic skin cancer, and the global numbers of patients dying from it exceed those linked to any other malignancy.

However, profound changes have been a notable development with respect to lung cancer over the last years. For one thing, shifts with regard to histology can be observed across the globe. The proportion of patients with small-cell lung cancer has been decreasing in frequency in many countries over the past two decades. Nonsmall lung cancer has undergone transformation concerning the relative importance of its predominant subtypes during the same period. In the USA, squamous cell carcinoma has decreased, while adenocarcinoma has increased in both genders. Similar trends apply to European men, while in women, both squamous-cell carcinoma and adenocarcinoma are currently on the rise.

Of course, from a clinician’s point of view, therapeutic innovation is the more spectacular part of lung-cancer–related changes. Novel approaches address targets that are not confined to the tumour cell, which had been at the centre of treatment considerations for a long time. Once again, immunotherapy was a hot topic at the ESMO 2016 Congress that took place in Copenhagen from 7th to 11th October. Renowned speakers presented four late-breaking abstracts on immunotherapeutic agents in advanced lung cancer at the second Presidential Symposium, which drew throngs of congress attendees. The results of these trials are presented in this publication, along with other findings in the field of immunotherapy.

Meanwhile, research has been ongoing with regard to druggable genetic aberrations within the tumour cell. Tyrosine kinase inhibitors like vandetanib and lenvatinib have shown promising clinical activity in RET-positive tumours, and convincing results were obtained with the next-generation ALK inhibitors ceritinib, alectinib and brigatinib. Recent insights into the EGFR landscape shed light on the refined use of EGFR-targeted drugs. At the same time, patients with small-cell histology find themselves entitled to share in the benefits conferred by molecularly targeted therapy. Aurora kinase A inhibition is a promising approach here, as is the PD- L1 antibody atezolizumab. Finally, the disruption of tumour angiogenesis contributes to tailoring treatment to each patient’s needs. Individualised therapy has become a reality for the benefit of a large number of present and future patients.

More posts

SCLC: genomic alterations pave the way to targeted approaches

Rapid growth and early development of metastatic disease are characteristic of small-cell lung cancer (SCLC), which constitutes approximately 15 % of all lung cancer cases. In limited-stage disease, a cure is possible with chemoradiotherapy. However, 68 % of patients present with extensive-stage SCLC (ES-SCLC). Although high initial responses to platinum-based chemotherapy and radiotherapy are observed, recurrence of chemo-refractory disease takes place as a rule.

Rare driver mutations: encouraging results in small patient populations

As well as ALK fusion mutations and EGFR mutations, studies of the genetic profiles of patients with NSCLC have identified other mutations that might be used for additional targeted therapies. Among these, ROS1 and RET rearrangements both occur in 1 % to 2 % of patients with NSCLC. Crizotinib is known to target not only ALK, but also ROS1, among others. Patients with ROS1-positive advanced NSCLC are being treated with crizotinib 250 mg twice daily in the ongoing phase I, open-label, PROFILE 1001 study.

EGFR-targeted therapy: at the right time in the right patient

Approximately 11 % of Caucasian patients with NSCLC have tumours that harbour EGFR mutations, which occur in exons 18, 19, 20 and 21 of the EGFR gene. Common mutations include exon 19 in-frame deletions and the exon 21 Leu858Arg point mutation (L858R). Exon 20 insertions are known to mediate resistance [3]. Little data are available for the other more uncommon mutations.

Next-generation ALK inhibitors excel after crizotinib failure

ALK fusion-gene–positive lung cancer occurs in approximately 5 % of patients with advanced NSCLC [1]. The ALK inhibitor crizotinib demonstrates significant initial efficacy in patients with ALK-positive advanced NSCLC.  However, most patients eventually develop resistance, with the central nervous system (CNS) being one of the most common sites of first progression.

Immune checkpoint inhibition: the picture is slowly completing itself

The anti–PD-1 antibody pembrolizumab has been approved for treatment of patients with PD-L1–expressing, advanced NSCLC. The KEYNOTE-024 study focused on the first-line comparison of pembrolizumab with platinum-doublet chemotherapy. Chemotherapy regimens comprised five options, two of which (pemetrexed plus carboplatin; pemetrexed plus cisplatin) were used with non-squamous non-small–cell lung cancer (NSCLC) only.